+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

NTRK Fusion Gene Positive Advanced Solid Tumor Market Outlook 2026-2034: by End-User (Hospitals & Clinics, Cancer Centers, Diagnostic Laboratories), Product Type, Tumor Origin

  • PDF Icon

    Report

  • 160 Pages
  • October 2026
  • Region: Global
  • OG Analysis
  • ID: 6243294
UP TO OFF until Jan 01st 2027
The NTRK Fusion Gene Positive Advanced Solid Tumor Market is estimated at US$497.7 million in 2026 and is projected to grow at a CAGR of 15.2% to reach US$1.54 billion by 2034.

Market Overview

The NTRK Fusion Gene Positive Advanced Solid Tumor Market covers targeted therapies and diagnostic pathways focused on advanced solid tumors that carry ntrk fusion gene alterations across precision oncology care.

Relevant uses and settings include molecular oncology testing, hospital cancer treatment, targeted therapy programs, specialty diagnostics, biomarker guided prescribing, and relapse management. Commercial considerations include small patient populations, diagnostic access barriers, resistance concerns, and reimbursement scrutiny around high value targeted cancer therapies.

Market Segmentation

By End-User

  • Hospitals & Clinics
  • Cancer Centers
  • Diagnostic Laboratories

By Product Type

  • Therapeutics
  • Diagnostics

By Tumor Origin

  • Thyroid Cancer
  • Salivary Gland Cancer
  • Lung Cancer (NSCLC)
  • Colorectal Cancer

Key Companies Analysed

  • Bayer
  • Eli Lilly
  • Roche
  • Pfizer
  • Bristol Myers Squibb
  • Merck KGaA
  • Blueprint Medicines
  • Turning Point Therapeutics
  • BeiGene
  • Takeda
  • Novartis
  • AstraZeneca
  • Boehringer Ingelheim
  • AbbVie
  • Amgen
  • Loxo Oncology
  • Bayer HealthCare
  • Genentech
  • Guardant Health
  • Foundation Medicine

Geographic Coverage

  • North America - Market data and outlook to 2034
    • United States
    • Canada
    • Mexico

  • Europe - Market data and outlook to 2034
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Netherlands
    • Switzerland
    • Poland
    • Sweden
    • Russia

  • Asia-Pacific - Market data and outlook to 2034
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Malaysia
    • Vietnam

  • Middle East and Africa - Market data and outlook to 2034
    • Saudi Arabia
    • South Africa
    • Iran
    • UAE
    • Egypt

  • South and Central America - Market data and outlook to 2034
    • Brazil
    • Argentina
    • Chile
    • Peru

*We can include data and analysis of additional countries on demand.

Report Delivery and Support

  • Updated PDF report and an MS Excel workbook containing market tables and figures.
  • 7-day post-sale analyst support for clarifications and in-scope supplementary data.
  • Complimentary report update covering the latest available data and relevant market developments.

This product will be delivered within 1-3 business days.

Table of Contents

1. Contents and Report Guide
1.1. List of Tables
1.2. List of Figures
2. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Overview
2.1. NTRK Fusion Gene Positive Advanced Solid Tumor Market Scope and Definitions
2.2. Research Methodology and Forecast Assumptions
2.3. Value Chain and Relevant Adjacent Markets
3. NTRK Fusion Gene Positive Advanced Solid Tumor Market Dynamics
3.1. Demand Drivers
3.2. Constraints and Adoption Barriers
3.3. Technology and Commercial Trends
3.4. Regulatory and Supply-Chain Considerations
4. NTRK Fusion Gene Positive Advanced Solid Tumor Market Strategic Analysis
4.1. Competitive Structure
4.2. Pricing and Purchasing Factors
4.3. Customer Requirements and Opportunity Assessment
5. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size, Share and Forecast, 2025-2034
5.1. Revenue Outlook, 2025-2034 (US$ million)
5.2. NTRK Fusion Gene Positive Advanced Solid Tumor Market Analysis By End-User, 2025-2034
5.2.1. Hospitals & Clinics
5.2.2. Cancer Centers
5.2.3. Diagnostic Laboratories
5.3. NTRK Fusion Gene Positive Advanced Solid Tumor Market Analysis By Product Type, 2025-2034
5.3.1. Therapeutics
5.3.2. Diagnostics
5.4. NTRK Fusion Gene Positive Advanced Solid Tumor Market Analysis By Tumor Origin, 2025-2034
5.4.1. Thyroid Cancer
5.4.2. Salivary Gland Cancer
5.4.3. Lung Cancer (NSCLC)
5.4.4. Colorectal Cancer
6. North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Outlook to 2034
6.1. North America Market Snapshot
6.2. North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Analysis By End-User
6.3. North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Analysis By Product Type
6.4. North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Analysis By Tumor Origin
6.5. North America Outlook By Country
6.5.1. United States
6.5.2. Canada
6.5.3. Mexico
7. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Outlook to 2034
7.1. Europe Market Snapshot
7.2. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Analysis By End-User
7.3. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Analysis By Product Type
7.4. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Analysis By Tumor Origin
7.5. Europe Outlook By Country
7.5.1. Germany
7.5.2. United Kingdom
7.5.3. France
7.5.4. Italy
7.5.5. Spain
7.5.6. Netherlands
7.5.7. Switzerland
7.5.8. Poland
7.5.9. Sweden
7.5.10. Russia
8. Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Outlook to 2034
8.1. Asia-Pacific Market Snapshot
8.2. Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Analysis By End-User
8.3. Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Analysis By Product Type
8.4. Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Analysis By Tumor Origin
8.5. Asia-Pacific Outlook By Country
8.5.1. China
8.5.2. Japan
8.5.3. India
8.5.4. South Korea
8.5.5. Australia
8.5.6. Indonesia
8.5.7. Malaysia
8.5.8. Vietnam
9. Middle East and Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Outlook to 2034
9.1. Middle East and Africa Market Snapshot
9.2. Middle East and Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Analysis By End-User
9.3. Middle East and Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Analysis By Product Type
9.4. Middle East and Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Analysis By Tumor Origin
9.5. Middle East and Africa Outlook By Country
9.5.1. Saudi Arabia
9.5.2. South Africa
9.5.3. Iran
9.5.4. United Arab Emirates
9.5.5. Egypt
10. South and Central America NTRK Fusion Gene Positive Advanced Solid Tumor Market Outlook to 2034
10.1. South and Central America Market Snapshot
10.2. South and Central America NTRK Fusion Gene Positive Advanced Solid Tumor Market Analysis By End-User
10.3. South and Central America NTRK Fusion Gene Positive Advanced Solid Tumor Market Analysis By Product Type
10.4. South and Central America NTRK Fusion Gene Positive Advanced Solid Tumor Market Analysis By Tumor Origin
10.5. South and Central America Outlook By Country
10.5.1. Brazil
10.5.2. Argentina
10.5.3. Chile
10.5.4. Peru
11. NTRK Fusion Gene Positive Advanced Solid Tumor Market Competitive Landscape
11.1. Market Participants and Strategic Positioning
11.2. Company Profiles: Product Portfolios, Positioning and Strategies
11.2.1. Bayer
11.2.2. Eli Lilly
11.2.3. Roche
11.2.4. Pfizer
11.2.5. Bristol Myers Squibb
11.2.6. Merck KGaA
11.2.7. Blueprint Medicines
11.2.8. Turning Point Therapeutics
11.2.9. BeiGene
11.2.10. Takeda
11.2.11. Novartis
11.2.12. AstraZeneca
11.2.13. Boehringer Ingelheim
11.2.14. AbbVie
11.2.15. Amgen
11.2.16. Loxo Oncology
11.2.17. Bayer HealthCare
11.2.18. Genentech
11.2.19. Guardant Health
11.2.20. Foundation Medicine
12. Appendix
12.1. Definitions and Abbreviations
12.2. Data Sources and Methodology
12.3. Publisher Information

Companies Mentioned

  • Bayer
  • Eli Lilly
  • Roche
  • Pfizer
  • Bristol Myers Squibb
  • Merck KGaA
  • Blueprint Medicines
  • Turning Point Therapeutics
  • BeiGene
  • Takeda
  • Novartis
  • AstraZeneca
  • Boehringer Ingelheim
  • AbbVie
  • Amgen
  • Loxo Oncology
  • Bayer HealthCare
  • Genentech
  • Guardant Health
  • Foundation Medicine

Table Information